2 assets in Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disease

Therapeutic assets addressing Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disease	Medical College of Wisconsin	P1	CC (43)
Gm-Csf Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disease	Medical College of Wisconsin	P1	CC (43)